Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study
暂无分享,去创建一个
Pierre-Yves Dumas | Dominique Bordessoule | Fabrice Jardin | R. Porcher | F. Jardin | M. Mohty | P. Rohrlich | J. Mary | L. Fornecker | B. Mahé | G. Socié | F. Barraco | S. de Guibert | B. Royer | Raphael Porcher | Jean-Yves Mary | B. Corront | Mohamad Mohty | Michael Loschi | Fiorenza Barraco | Louis Terriou | Sophie de Guibert | Beatrice Mahe | Richard Lemal | Gabriel Etienne | Bruno Royer | Pierre Simon Rohrlich | Luc Mathieu Fornecker | Celia Salanoubat | Sebastien Maury | Jean-Yves Cahn | Laure Vincent | Thomas Sene | Sophie Rigaudeau | Stephanie Nguyen | Anne-Claire Lepretre | Bernadette Corront | Gerard Socie | Regis Peffault de Latour | J. Cahn | S. Maury | D. Bordessoule | S. Rigaudeau | G. Étienne | P. Dumas | S. Nguyen | R. Peffault de Latour | C. Salanoubat | L. Terriou | M. Loschi | L. Vincent | T. Sené | R. Lemal | A. Lepretre | B. Mahé
[1] W. Rosse,et al. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. , 1996, Blood.
[2] M. Gladwin,et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria , 2010, British journal of haematology.
[3] A. Tichelli,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. , 1993, The New England journal of medicine.
[4] M. Mohty,et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. , 2008, Blood.
[5] R. Brodsky,et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.
[6] W. Rosse. Dr Ham's test revisited [editorial] , 1991 .
[7] P. Hillmen,et al. Thrombosis in paroxysmal nocturnal hemoglobinuria. , 2013, Blood.
[8] W. Rosse,et al. The natural history of paroxysmal nocturnal hemoglobinuria. , 1997, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
[9] J. Lunceford,et al. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.
[10] J. Robins,et al. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.
[11] N. Young,et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. , 2007, Blood.
[12] E. S. Garrett,et al. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays , 2004, British journal of haematology.
[13] M. Desierto,et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. , 2010, Blood.
[14] D B Rubin,et al. Multiple imputation in health-care databases: an overview and some applications. , 1991, Statistics in medicine.
[15] G. Khursigara,et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria , 2010, American journal of hematology.
[16] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[17] D. Blaise,et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria , 2012, Haematologica.
[18] F. Craig,et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry , 2010, Cytometry. Part B, Clinical cytometry.
[19] J. Maciejewski,et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria , 2013, British journal of haematology.
[20] M. Gladwin,et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.
[21] K. Ozawa,et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial , 2013, International Journal of Hematology.
[22] S. Richards,et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization , 2010, Haematologica.
[23] W. Gregory,et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. , 2010, Blood.
[24] Neal Young,et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.
[25] R. Porcher,et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. , 2015, Blood.